Smith & Nephew plc (LON:SN – Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,061.05 ($14.21) and traded as high as GBX 1,157 ($15.49). Smith & Nephew shares last traded at GBX 1,151.50 ($15.42), with a volume of 708,297 shares traded.
Analyst Ratings Changes
Separately, Berenberg Bank restated a “buy” rating and issued a £145 ($194.16) price target on shares of Smith & Nephew in a research report on Monday, August 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of GBX 3,956.20 ($52.98).
Read Our Latest Research Report on Smith & Nephew
Smith & Nephew Stock Up 0.1 %
Smith & Nephew Cuts Dividend
The business also recently declared a dividend, which will be paid on Friday, November 8th. Investors of record on Thursday, October 3rd will be issued a dividend of $0.14 per share. The ex-dividend date is Thursday, October 3rd. This represents a yield of 1%. Smith & Nephew’s dividend payout ratio (DPR) is currently 11,538.46%.
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Recommended Stories
- Five stocks we like better than Smith & Nephew
- When to Sell a Stock for Profit or Loss
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Retail Stocks Investing, Explained
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What is a Low P/E Ratio and What Does it Tell Investors?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.